SG11201507507PA - Compositions and methods for treating mpsi - Google Patents

Compositions and methods for treating mpsi

Info

Publication number
SG11201507507PA
SG11201507507PA SG11201507507PA SG11201507507PA SG11201507507PA SG 11201507507P A SG11201507507P A SG 11201507507PA SG 11201507507P A SG11201507507P A SG 11201507507PA SG 11201507507P A SG11201507507P A SG 11201507507PA SG 11201507507P A SG11201507507P A SG 11201507507PA
Authority
SG
Singapore
Prior art keywords
compositions
methods
mpsi
treating
treating mpsi
Prior art date
Application number
SG11201507507PA
Inventor
James M Wilson
Brittney L Gurda
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of SG11201507507PA publication Critical patent/SG11201507507PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076L-Iduronidase (3.2.1.76)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SG11201507507PA 2013-03-15 2014-03-13 Compositions and methods for treating mpsi SG11201507507PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788724P 2013-03-15 2013-03-15
PCT/US2014/025509 WO2014151341A1 (en) 2013-03-15 2014-03-13 Compositions and methods for treating mpsi

Publications (1)

Publication Number Publication Date
SG11201507507PA true SG11201507507PA (en) 2015-10-29

Family

ID=51580934

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201707319UA SG10201707319UA (en) 2013-03-15 2014-03-13 Compositions and methods for treating mpsi
SG11201507507PA SG11201507507PA (en) 2013-03-15 2014-03-13 Compositions and methods for treating mpsi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201707319UA SG10201707319UA (en) 2013-03-15 2014-03-13 Compositions and methods for treating mpsi

Country Status (22)

Country Link
US (3) US10137176B2 (en)
EP (2) EP2984166B1 (en)
JP (4) JP6591956B2 (en)
KR (2) KR102581652B1 (en)
CN (1) CN105026554B (en)
AU (2) AU2014235096B2 (en)
BR (1) BR112015021036A2 (en)
CA (1) CA2901328C (en)
CY (1) CY1123169T1 (en)
DK (1) DK2984166T3 (en)
ES (1) ES2805355T3 (en)
HK (1) HK1221735A1 (en)
HR (1) HRP20201063T1 (en)
HU (1) HUE051373T2 (en)
LT (1) LT2984166T (en)
MX (2) MX2015012739A (en)
PL (1) PL2984166T3 (en)
PT (1) PT2984166T (en)
RU (1) RU2708318C2 (en)
SG (2) SG10201707319UA (en)
SI (1) SI2984166T1 (en)
WO (1) WO2014151341A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2984166T (en) 2013-03-15 2020-07-16 Univ Pennsylvania Compositions and methods for treating mpsi
CA2946392A1 (en) * 2014-04-25 2015-10-29 James M. Wilson Ldlr variants and their use in compositions for reducing cholesterol levels
JP7061067B2 (en) * 2015-12-14 2022-04-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Composition for the treatment of Crigler-Najer syndrome
BR112018015751A2 (en) 2016-02-03 2019-02-05 Univ Pennsylvania gene therapy for treatment of mucopolysaccharidosis type i
WO2017136533A1 (en) * 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Methods for treating diagnosing, and monitoring treatment of mucopolysaccharidoses
WO2017147123A1 (en) * 2016-02-22 2017-08-31 The University Of North Carolina At Chapel Hill Aav-idua vector for treatment of mps i-associated blindness
KR20190008237A (en) 2016-04-15 2019-01-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Gene therapy for the treatment of type II mucopolysaccharidosis
KR102574810B1 (en) * 2016-04-15 2023-09-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Compositions for the treatment of wet age-related macular degeneration
WO2018022511A1 (en) 2016-07-25 2018-02-01 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
CN109715650B (en) 2016-07-26 2024-03-08 生物马林药物股份有限公司 Novel adeno-associated viral capsid proteins
CN110325199A (en) 2016-12-30 2019-10-11 宾夕法尼亚州立大学托管会 For treating the gene therapy of phenylketonuria
BR112020000063A2 (en) 2017-07-06 2020-07-14 The Trustees Of The University Of Pennsylvania aav9-mediated gene therapy for the treatment of type i mucopolysaccharidosis
JP7449223B2 (en) 2017-09-22 2024-03-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Gene therapy to treat mucopolysaccharidosis type II
CN107699590A (en) * 2017-10-13 2018-02-16 成都中医药大学 A kind of method of Prepare restructuring people α L iduronases
MX2020005673A (en) 2017-11-30 2020-12-03 Univ Pennsylvania Gene therapy for mucopolysaccharidosis iiib.
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
US11306329B2 (en) 2018-02-19 2022-04-19 City Of Hope Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
SG11202010830WA (en) 2018-05-09 2020-11-27 Biomarin Pharm Inc Methods of treating phenylketonuria
TW202005978A (en) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 Novel liver targeting adeno-associated viral vectors
CN113924115A (en) 2019-01-31 2022-01-11 俄勒冈健康与科学大学 Methods for AAV capsids using transcription-dependent directed evolution
TW202140791A (en) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 Methods of treating phenylketonuria
US20230304034A1 (en) 2020-05-12 2023-09-28 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
CA3183153A1 (en) 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
EP4225906A1 (en) 2020-10-09 2023-08-16 The Trustees of The University of Pennsylvania Compositions and methods for treatment of fabry disease
KR102590276B1 (en) * 2021-01-04 2023-10-16 부산대학교 산학협력단 Fusion promoter for tissue-specific expression, and use Thereof
CA3209779A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
EP4148078A1 (en) 2021-09-08 2023-03-15 Covestro Deutschland AG Succinic acid based polyester polyols
CN114181318B (en) * 2021-11-08 2023-08-01 四川大学 Recombinant adeno-associated virus for tissue-specific expression of IDUA fusion protein penetrating blood brain barrier and application thereof
WO2023087019A2 (en) 2021-11-15 2023-05-19 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2023102517A1 (en) 2021-12-02 2023-06-08 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
WO2023196892A1 (en) 2022-04-06 2023-10-12 The Trustees Of The University Of Pennsylvania Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
WO2023196893A1 (en) 2022-04-06 2023-10-12 The Trustees Of The University Of Pennsylvania Compositions and methods for treating her2 positive metastatic breast cancer and other cancers

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149909A (en) * 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
EP1078075A2 (en) 1998-05-13 2001-02-28 Harbor-Ucla Research and Education Institute Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
ATE403715T1 (en) 1999-08-09 2008-08-15 Targeted Genetics Corp INCREASE THE EXPRESSION OF A SINGLE STRANDED, HETEROLOGUE NUCLEOTIDE SEQUENCE FROM A RECOMBINANT VIRAL VECTOR BY DESIGNING THE SEQUENCE IN A WAY THAT CREATE BASE PAIRINGS WITHIN THE SEQUENCE
US6426208B1 (en) * 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
RU2196988C2 (en) 2000-04-19 2003-01-20 Государственный новосибирский областной клинический диагностический центр Method for diagnostics of mucopolysaccharidosis
DK1310571T3 (en) 2001-11-13 2006-06-19 Univ Pennsylvania Method for identifying unknown adeno-associated virus sequences (AAV sequences) and a kit for the method
EP1453547B1 (en) 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
AU2003302724A1 (en) 2002-08-13 2004-07-09 Mcivor, Scott, R. Methods of using vectors to treat metabolic disorders
US7155804B2 (en) 2003-09-17 2007-01-02 Moog Inc. Method of forming an electric motor
ES2411479T3 (en) 2003-09-30 2013-07-05 The Trustees Of The University Of Pennsylvania Adeno-associated virus clades (AAV), sequences, vectors that contain them, and uses thereof
EP3085389A1 (en) 2005-04-07 2016-10-26 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
US20090062144A1 (en) * 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
AU2010316996A1 (en) 2009-11-05 2012-06-14 Proyecto De Biomedicina Cima, S.L. Regulated expression systems
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
JP5922095B2 (en) 2010-03-29 2016-05-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Pharmacologically induced transgene ablation system
ES2698203T3 (en) 2010-04-23 2019-02-01 Univ Massachusetts AAV vectors that are directed to the SNC and methods of using them
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
US9222088B2 (en) * 2010-10-22 2015-12-29 Curna, Inc. Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
EP2675902B1 (en) 2011-02-17 2019-03-27 The Trustees Of The University Of Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
EP2699270B1 (en) 2011-04-22 2017-06-21 The Regents of The University of California Adeno-associated virus virions with variant capsid and methods of use thereof
AU2013289206B2 (en) 2012-07-11 2018-08-09 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of lysosomal storage diseases
JP6437443B2 (en) 2012-11-21 2018-12-12 アールキューエックス ファーマシューティカルズ,インク. Macrocyclic wide-area antibiotics
WO2014125647A1 (en) 2013-02-18 2014-08-21 富士通オプティカルコンポーネンツ株式会社 Photoreceptor device
PT2984166T (en) 2013-03-15 2020-07-16 Univ Pennsylvania Compositions and methods for treating mpsi
KR20160010526A (en) 2013-05-15 2016-01-27 리젠츠 오브 더 유니버시티 오브 미네소타 Adeno-associated virus mediated gene transfer to the central nervous system
BR112017005892A2 (en) 2014-09-24 2017-12-12 Hope City adeno-associated virus vector variants for high-efficiency genome editing and methods
RU2017115772A (en) 2014-10-06 2018-11-13 Артроджен Б. В. COMBINATION FOR GENOTHERAPY
WO2016187017A1 (en) 2015-05-15 2016-11-24 Mcivor R Scott Adeno-associated for therapeutic delivery to central nervous system
TWI617573B (en) 2015-08-06 2018-03-11 中央研究院 Engineered enzyme for enzyme replacement therapy
CN116650668A (en) 2015-10-23 2023-08-29 衣阿华大学研究基金会 Methods of treating neurodegenerative disorders using gene therapy to delay disease onset and progression while providing cognitive protection
WO2017160360A2 (en) 2015-12-11 2017-09-21 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
EP3387117B1 (en) 2015-12-11 2022-11-23 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
WO2017100674A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
US11028372B2 (en) 2015-12-11 2021-06-08 The Trustees Of The University Of Pennsylvania Scalable purification method for AAVRH10
ES2895430T3 (en) 2016-01-15 2022-02-21 Univ Minnesota Methods and compositions for the treatment of neurological disease
BR112018015751A2 (en) 2016-02-03 2019-02-05 Univ Pennsylvania gene therapy for treatment of mucopolysaccharidosis type i
BR112020000063A2 (en) 2017-07-06 2020-07-14 The Trustees Of The University Of Pennsylvania aav9-mediated gene therapy for the treatment of type i mucopolysaccharidosis

Also Published As

Publication number Publication date
JP2023011752A (en) 2023-01-24
HUE051373T2 (en) 2021-03-01
KR20220005599A (en) 2022-01-13
SI2984166T1 (en) 2020-09-30
DK2984166T3 (en) 2020-07-20
CN105026554B (en) 2020-08-11
JP2020202863A (en) 2020-12-24
US10792343B2 (en) 2020-10-06
CY1123169T1 (en) 2021-10-29
BR112015021036A2 (en) 2017-10-10
ES2805355T3 (en) 2021-02-11
US20200397872A1 (en) 2020-12-24
CA2901328C (en) 2023-08-01
EP3747998A1 (en) 2020-12-09
AU2014235096B2 (en) 2020-03-19
KR102581652B1 (en) 2023-09-22
HK1221735A1 (en) 2017-06-09
HRP20201063T1 (en) 2020-11-27
MX2015012739A (en) 2016-02-19
SG10201707319UA (en) 2017-10-30
JP6591956B2 (en) 2019-10-16
KR102346455B1 (en) 2022-01-04
PT2984166T (en) 2020-07-16
KR20150129678A (en) 2015-11-20
PL2984166T3 (en) 2021-01-11
JP7168621B2 (en) 2022-11-09
AU2020203826B2 (en) 2022-09-15
LT2984166T (en) 2020-08-10
JP2019134717A (en) 2019-08-15
RU2015144234A (en) 2017-04-24
MX2021010918A (en) 2021-10-01
RU2708318C2 (en) 2019-12-05
US20190111116A1 (en) 2019-04-18
EP2984166A4 (en) 2016-09-07
US10137176B2 (en) 2018-11-27
EP2984166A1 (en) 2016-02-17
CA2901328A1 (en) 2014-09-25
EP3747998A9 (en) 2021-08-04
AU2014235096A1 (en) 2015-09-10
CN105026554A (en) 2015-11-04
EP2984166B1 (en) 2020-04-22
US20160000887A1 (en) 2016-01-07
WO2014151341A1 (en) 2014-09-25
JP2016512683A (en) 2016-05-09
AU2020203826A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
HK1221735A1 (en) Compositions and methods for treating mpsi mps1
IL281058A (en) Compositions and methods for treating anemia
IL245778B (en) Methods and compositions for treating hemophilia
IL245281A0 (en) Methods and compositions for treating cancer
ZA201505390B (en) Compositions and methods for treating pests
EP2950884A4 (en) Compositions and methods for treating surface wounds
IL244118A0 (en) Compositions and methods for treating chronic urticaria
HK1255453A1 (en) Methods and compositions for treating leukemia
HK1225647A1 (en) Compositions and methods for treating cancers
EP2989123A4 (en) Methods and compositions for treating bleeding disorders
SG11201510300RA (en) Compositions and methods for treating skin
IL243022B (en) Compositions and methods for post-harvest treatment
HK1222323A1 (en) Compositions and methods for treating conditions that affect epidermis
EP2971044A4 (en) Compositions and methods for treating cancer
ZA201408732B (en) Composition and methods for treating wounds
GB201302472D0 (en) Compositions and methods for treating biofilms
GB201302474D0 (en) Compositions and methods for treating biofilms